Current Edition


ProQR to lay off 30% of staff following eye drug setback

Dive Brief: ProQR Therapeutics is overhauling its research, cutting staff and trying to find a new way forward for its lead drug after a surprising …

Continue Reading →

Lilly joins RNA editing race with ProQR deal

Much of the attention in the genetic editing world in recent years has been on CRISPR and the “genetic scissors” that allow researchers to make …

Continue Reading →